EGFR and familial pancreatic carcinoma: Recently, a few other studies also revealed a change in ligand behavior after conjugation to NPs: It has been demonstrated in pancreatic cancer cell lines that anti-EGFR antibody-gold nanoparticle conjugates used different and faster endocytosis mechanisms than the anti-EGFR antibody itself [27], and the valency of TatP domains conjugated to QDs affected the fate of the NPs [28].